Astellas Pharma
-
Astellas Drug Acquired in $5.9B Deal Wins FDA Approval in Vision-Loss Disorder
Izervay, a drug developed by Astellas Pharma subsidiary Iveric Bio, is now the second approved therapy for the degenerative vision-loss disorder geographic atrophy. The regulatory decision comes as safety concerns emerge around the first therapy for the disease, an Apellis Pharmaceuticals product.
-
Astellas Strikes Another Deal to Expand in Cancer, Partnering With PeptiDream
Astellas Pharma has identified targeted protein degradation as one of the key areas for growth. The PeptiDream alliance is the latest one Astellas has struck in this particular area of drug research as it aims to find new ways to go after difficult cancer targets.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
FDA Approves First-Of-Its Kind Drug to Ease Menopause Symptoms
Astellas Pharma won FDA approval for Veozah, a new menopause drug. The once-daily pill offers a new non-hormonal treatment option for addressing menopausal symptoms.
-
Eyeing Its Next Blockbuster, Astellas Lines Up $5.9B Iveric Bio Acquisition
Astellas Pharma is acquiring Iveric Bio in a deal that brings a vision loss-disorder drug on track for an FDA decision this summer. Iveric’s pipeline also includes genetic medicines that fit Astellas’s gene therapy strategy.
-
Digital transformation: Reimagining clinical trial management
Decentralized clinical trial approaches helped the pharma industry navigate through Covid-19. Now it is becoming increasingly clear that there’s a need for a hybrid approach to decentralized clinical trials that considers the perspectives of patients and the impact to clinical trial sites.
-
Astellas pays Sutro Bio $90M to partner on cancer drugs that make cold tumors hot
Astellas Pharma has a new partner in the R&D of a type of cancer drug called an antibody drug conjugate (ADC). The Japanese pharma company reached across the Pacific Ocean to collaborate with Sutro Biopharma in a bet that Bay Area-based firm’s technology can deliver more powerful ADCs.
-
Astellas Pharma reports fourth patient death in gene therapy clinical trial
The death occurred less than two weeks after Astellas Pharma reported that the patient developed liver problems after being dosed with the experimental gene therapy for a rare neuromuscular disorder. Astellas said the cause of death is still under investigation, and the FDA has placed a clinical hold on the study.
-
Astellas’ Audentes Therapeutics discloses third patient death in gene therapy trial
The clinical trial had already been placed on hold in connection with the two prior patient deaths, which were linked to the higher dose of 300 trillion viral vectors per kilogram, while no deaths have been reported among those receiving the lower dose of 100 trillion vectors.
-
Audentes – bought by Astellas for $3B – discloses new patient death, gene therapy trial hold
The company disclosed in a letter to the X-linked myotubular myopathy patient community that a second child in its Phase I/II study had died. A formal clinical hold has been placed on the trial.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Astellas partners with Adaptimmune in latest move into cell therapy
The companies will work to develop allogeneic CAR-T and T-cell receptor therapies. Astellas has made multiple moves into cell and gene therapy in the past month.
-
Astellas buys Xyphos – and its cell therapy platform – for $665M
The deal comes less than a month after the Japanese drugmaker said it would spend $3 billion to acquire gene therapy developer Audentes Therapeutics.
-
Astellas dives into gene therapy with $3B acquisition of Audentes Therapeutics
Shares of Audentes rose more than 100% following news that the Japanese drugmaker would acquire it. The company’s lead candidate is a gene therapy for a rare muscular weakness disorder, currently in a Phase I/II study for which it presented data in October.
-
Artificial Intelligence, BioPharma
Concerto HealthAI, Astellas partner on RWE in acute myeloid leukemia
The partnership will focus on using real-world evidence to improve understanding of responses among patients with acute myeloid leukemia whose disease carries mutations in the FLT3 gene. Astellas markets a drug for FLT3-positive AML, Xospata, approved in November.
-
Astellas’s Xospata in AML scores a goal with new Phase III survival data at AACR
The drug was approved for FLT3-mutated acute myeloid leukemia in November based on response rate data, but the latest results show improvement on the gold-standard measure of overall survival.
-
FDA approves Astellas’ Xospata for FLT3-mutated acute myeloid leukemia
The drug is the second FLT3 inhibitor to win approval, after Novartis’ Rydapt in first-line disease. Daiichi Sankyo’s quizartinib could present competition if it wins approval, but it would target a somewhat narrower population of FLT3-mutated patients.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
